Eyepoint Pharmaceuticals (EYPT) Competitors

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Eyepoint Pharmaceuticals has a consensus target price of $44.38, suggesting a potential upside of 200.85%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Eyepoint Pharmaceuticals' return on equity.

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

In the previous week, Eyepoint Pharmaceuticals had 22 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 22 mentions for Eyepoint Pharmaceuticals and 0 mentions for Catalyst Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.03 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Eyepoint Pharmaceuticals had 10 more articles in the media than Structure Therapeutics. MarketBeat recorded 22 mentions for Eyepoint Pharmaceuticals and 12 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.04 beat Eyepoint Pharmaceuticals' score of 0.03 indicating that Structure Therapeutics is being referred to more favorably in the media.

Structure Therapeutics presently has a consensus target price of $110.91, suggesting a potential upside of 103.47%. Eyepoint Pharmaceuticals has a consensus target price of $44.38, suggesting a potential upside of 200.85%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Structure Therapeutics.

Structure Therapeutics has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Structure Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Structure Therapeutics' return on equity of -26.12% beat Eyepoint Pharmaceuticals' return on equity.

Structure Therapeutics has a beta of -1.43, suggesting that its stock price is 243% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

In the previous week, Eyepoint Pharmaceuticals had 15 more articles in the media than Organon & Co.. MarketBeat recorded 22 mentions for Eyepoint Pharmaceuticals and 7 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.92 beat Eyepoint Pharmaceuticals' score of 0.03 indicating that Organon & Co. is being referred to more favorably in the media.

Organon & Co. presently has a consensus price target of $11.40, indicating a potential downside of 16.88%. Eyepoint Pharmaceuticals has a consensus price target of $44.38, indicating a potential upside of 200.85%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Organon & Co..

Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Organon & Co. has a net margin of 3.41% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Organon & Co.'s return on equity of 88.97% beat Eyepoint Pharmaceuticals' return on equity.

Eyepoint Pharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 23 mentions for Arcutis Biotherapeutics and 22 mentions for Eyepoint Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.74 beat Eyepoint Pharmaceuticals' score of 0.03 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Eyepoint Pharmaceuticals presently has a consensus price target of $44.38, indicating a potential upside of 200.85%. Arcutis Biotherapeutics has a consensus price target of $35.57, indicating a potential upside of 35.82%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Arcutis Biotherapeutics.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Arcutis Biotherapeutics has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Arcutis Biotherapeutics' return on equity of 15.05% beat Eyepoint Pharmaceuticals' return on equity.